
Panelists answer audience questions on treatment targets, fertility-sparing options, and formulations, and why lifestyle change and therapy pair well.
"For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.
In this interview, Phillip H. Kuo, MD, PhD, FACR, shares key findings and takeaways from the study, “Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial),”1 for which he served as the lead author. Kuo is a professor of radiology, section chief of nuclear medicine, and director of theranostics for the department of radiology at City of Hope National Medical Center in Duarte, California.





